Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill shows promise for tough eczema in small study

NCT ID NCT06585202

Disease control Sponsor: Aclaris Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental oral drug called ATI-2138 in 14 adults with moderate to severe atopic dermatitis (eczema). Participants took the pill twice daily for 12 weeks. Researchers tracked safety, side effects, and skin improvement using standard eczema scores. The goal was to see if the drug is safe and might reduce skin redness, itching, and rash.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ATI-2138 oral tablets
What this could lead to
If successful, this could point toward a new oral treatment option for moderate to severe atopic dermatitis, potentially reducing skin inflammation and itching.
What could go wrong
This is a small, early-phase study with only 14 participants and no placebo group, so results may not apply broadly. Side effects are possible, and the drug may not prove effective in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

14 people

The number who actually took part.

Started

Aug 2024

Finished

Mar 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to comprehend and willing to sign the IRB approved ICF/assent prior to administration of study-related procedures. * Male patients or non-pregnant, non-nursing female patients 18 to 60 years old, inclusive, at the time of informed consent/assent. * Have at least a 1-year history of moderate or severe AD prior to the Screening Visit, and no significant AD flares for the 4 weeks prior to the Screening Visit as determined by the Investigator upon review of participant medical history. Exclusion Criteria: * Any prior exposure to systemic (oral) JAK inhibitors or TYK inhibitors at any time prior to Screening. * Unstable course of AD (spontaneously improving or rapidly deteriorating) based on the patient history or as determined by the investigator during the Screening Period. * Refractory AD (ie, AD that required frequent hospitalizations and/or frequent intravenous treatment for skin infections within the year before the Screening Visit). * Concomitant skin disease or clinically infected AD or presence of other skin disease in the area to be dosed that may interfere with study assessments. * Female patients who are pregnant, nursing, or planning to become pregnant during the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema dermatitis Eczema Skin Diseases, Eczematous skin disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

Contacts and locations

Locations

  • Aclaris Investigational Site

    Birmingham, Alabama, 35244, United States

  • Aclaris Investigational Site

    Encino, California, 91436, United States

  • Aclaris Investigational Site

    San Diego, California, 92123, United States

  • Aclaris Investigational Site

    Plainfield, Indiana, 46168, United States

  • Aclaris Investigational Site

    Austin, Texas, 78759, United States

  • Aclaris Investigational Site

    San Antonio, Texas, 78213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.